Drug intelligence / Profile preview

2'-(4-dimethylaminophenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazole

Development stage: Unknown
Modality: Small Molecules

Overview

This compound is a synthetic small molecule belonging to the phenylbenzimidazole class. It is primarily used as a research chemical and has not been approved for clinical use in any country. The molecule features two benzimidazole rings connected via a biaryl linkage, with one ring substituted by a 4-dimethylaminophenyl group and the other by a 4-methylpiperazinyl group. There are no known indications or approved therapeutic uses for this compound. Its mechanism of action has not been characterized in the literature or drug databases[1][3][7].

Other names: 2'-(4-dimethylaminophenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazoleBBZ

Beyond the preview

Go deeper on 2'-(4-dimethylaminophenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2'-(4-dimethylaminophenyl)-5-(4-methyl-1-piperazinyl)-2,5'-bi-benzimidazole.

Explore the full profile